Stay updated on Gilteritinib vs Midostaurin in AML Clinical Trial

Sign up to get notified when there's something new on the Gilteritinib vs Midostaurin in AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Gilteritinib vs Midostaurin in AML Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    5%
    Check dated 2025-03-03T22:23:08.000Z thumbnail image
  3. Check
    26 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    5%
    Check dated 2025-02-10T09:47:18.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.3%
    Check dated 2025-02-03T07:52:57.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.3%
    Check dated 2025-01-19T22:35:40.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in its functionality.
    Difference
    0.9%
    Check dated 2025-01-12T17:56:14.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    A new addition was made on December 17, 2024, while content from June 15, 2023, has been removed.
    Difference
    0.9%
    Check dated 2024-12-21T23:49:17.000Z thumbnail image

Stay in the know with updates to Gilteritinib vs Midostaurin in AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Gilteritinib vs Midostaurin in AML Clinical Trial page.